GW Pharmaceuticals PLC (GWPH)
Stock Price:
$91.01 USD
-3.99 (-4.20%)
Updated Oct 26, 2020 1:32 PM EDT - Market open
Key Info
| Market Cap |
2.83B |
| Revenue (ttm) |
441.98M |
| Net Income (ttm) |
-55.50M |
| Shares Out |
31.14M |
| EPS (ttm) |
-1.78 |
| PE Ratio |
n/a |
| Forward PE |
103.09 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$91.01 |
| Previous Close |
$95.00 |
| Change ($) |
-3.99 |
| Change (%) |
-4.20% |
| Day's Open |
94.57 |
| Day's Range |
90.85 - 95.49 |
| Day's Volume |
205,297 |
| 52-Week Range |
67.98 - 141.98 |
More Stats
| Market Cap |
2.83B |
| Enterprise Value |
2.38B |
| Earnings Date (est) |
Nov 3, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
31.14M |
| Float |
25.61M |
| EPS (basic) |
-0.02 |
| EPS (diluted) |
-1.78 |
| FCF / Share |
-3.39 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.96M |
| Short Ratio |
12.25 |
| Short % of Float |
19.35% |
| Beta |
1.74 |
| PE Ratio |
n/a |
| Forward PE |
103.09 |
| P/FCF Ratio |
n/a |
| PS Ratio |
6.41 |
| PB Ratio |
4.22 |
| Revenue |
441.98M |
| Operating Income |
-54.00M |
| Net Income |
-55.50M |
| Free Cash Flow |
-106.13M |
| Net Cash |
452.83M |
| Net Cash / Share |
14.54 |
| Gross Margin |
64.29% |
| Operating Margin |
-12.22% |
| Profit Margin |
-12.60% |
| FCF Margin |
-24.01% |
| ROA |
-3.94% |
| ROE |
-7.68% |
| ROIC |
-19.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (17)
| Buy |
15 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$190.38*
(109.19% upside)
Low
136
Current: $91.01
High
275
Target: 190.38
*Average 12-month price target from 16 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 311 | 12.74 | 8.63 | 12.73 |
| Revenue Growth | 2344.31% | 47.61% | -32.22% | - |
| Gross Profit | 284 | 6.75 | 4.11 | 8.91 |
| Operating Income | -118 | -289 | -166 | -129 |
| Net Income | -9.02 | -295 | -170 | -91.70 |
| Shares Outstanding | 372 | 334 | 306 | 272 |
| Earnings Per Share | - | -0.11 | -0.07 | -0.04 |
| Operating Cash Flow | -123 | -232 | -149 | -120 |
| Capital Expenditures | 61.63 | -32.89 | -20.10 | -12.91 |
| Free Cash Flow | -61.84 | -265 | -169 | -133 |
| Cash & Equivalents | 537 | 355 | 322 | - |
| Total Debt | 27.22 | 5.91 | 6.35 | - |
| Net Cash / Debt | 510 | 349 | 316 | - |
| Assets | 882 | 491 | 443 | - |
| Liabilities | 156 | 75.38 | 62.10 | - |
| Book Value | 726 | 415 | 381 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
GW Pharmaceuticals PLC |
| Country |
United Kingdom |
| Employees |
901 |
| CEO |
Justin D. Gover |
Stock Information
| Ticker Symbol |
GWPH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—General |
| Unique Identifier |
NASDAQ: GWPH |
| IPO Date |
May 1, 2013 |
Description
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.